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Abstract
Discontinuous entities pose a challenge to
named entity recognition (NER). These phe-
nomena occur commonly in the biomedical do-
main. As a solution, expansions of the BIO
representation scheme that can handle these
entity types are commonly used (i.e. BIOHD).
However, the extra tag types make the NER
task more difficult to learn. In this paper
we propose an alternative; a fuzzy continu-
ous BIO scheme (FuzzyBIO). We focus on
the task of Adverse Drug Response extraction
and normalization to compare FuzzyBIO to
BIOHD. We find that FuzzyBIO improves re-
call of NER for two of three data sets and re-
sults in a higher percentage of correctly identi-
fied disjoint and composite entities for all data
sets. Using FuzzyBIO also improves end-to-
end performance for continuous and compos-
ite entities in two of three data sets. Since
FuzzyBIO improves performance for some
data sets and the conversion from BIOHD to
FuzzyBIO is straightforward, we recommend
investigating which is more effective for any
data set containing discontinuous entities.
1 Introduction
Adverse Drug Reactions (ADRs), harmful reac-
tions that result from the intake of medication, pose
a major health concern (World Health Organisation,
2006). Due to the limitations of clinical trials on
the one hand (Shenoy and Harugeri, 2015) and
reporting systems after release on the market on
the other hand (Hazell and Shakir, 2006), many
ADRs remain undiscovered. Therefore, both social
media and clinical reports are being explored by
the research community as alternative information
sources for the semi-automatic discovery of ADRs
(Lardon et al., 2015; Sarker et al., 2015).
One particular challenge for the extraction of
ADRs from text is the presence of discontinuous
entities. These can be either composite entities (i.e.
some words belong to multiple entities), such as
‘lack of sleep and appetite’, or disjoint entities (i.e.
split entities), such as ‘eyes are feeling dry’. These
phenomena occur more commonly in the clinical
than general domain. In fact, Tang et al. (2015) re-
ported that discontinuous mentions in clinical text
account for about 10% of all ADR mentions. None
of the traditional versions of the BIO representation
scheme (B: beginning of entity, I: inside entity and
O: outside entity) or common extensions such as
IOBES (E: end of entity, S: singleton entity)1 were
designed to handle such mentions (Pradhan et al.,
2014). Therefore, Tang et al. (2015) proposed ex-
tending the BIO scheme with two additional tags:
the ‘H’ for words shared by multiple mentions and
‘D’ for parts of discontinuous mentions not shared
by other mentions. This resulted in four new tag
types (HB-, HI-, DB- and DI-). Their BIOHD rep-
resentation was broadly adopted by the community
(Karimi et al., 2015; Zolnoori et al., 2019; Si et al.,
2019). Table 1 shows examples of concepts repre-
sented with the BIOHD scheme.
Although the BIOHD scheme allows for precise
representation of entities, the extra tag types make
the task more difficult for models to learn. Straight-
forward BIO rules such as ‘an entity always starts
with a B’ are no longer valid under the BIOHD
scheme. In this paper we argue that a more simple
BIO representation in which discontinuous enti-
ties are transformed into continuous sequences by
including all non-entity tokens in between would
improve ADR extraction by being easier to learn
and reintroducing these straightforward rules. We
coin this representation FuzzyBIO. Some examples
of entities represented with BIOHD and FuzzyBIO
can be seen in Table 1.
Aside from improving extraction, using Fuzzy-
BIO instead of BIOHD may also improve sub-
1This scheme is also called BIOES, BILOU or BMEWO
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Sentence 1 Muscles are constantly quivering !
BIOHD DB O O DI O
FuzzyBIO B I I I O
Sentence 2 I have pain in my hands and upper arms
BIOHD O O HB HI HI DB O DB DI
FuzzyBIO O O B I I I I I I
Table 1: Examples of discontinuous disjoint (sentence 1) and composite (sentence 2) ADR mentions represented
by the BIOHD and FuzzyBIO schemes.
sequent concept normalization, in which ADRs
are linked to standardized medical concepts (e.g.
‘can’t fall asleep’ to the concept ‘insomnia’ with
concept identifier 193462001 in the medical on-
tology SNOMED-CT). This step is essential for
aggregating and thus quantifying the prevalence of
ADR. As current normalization methods are mostly
hampered by errors made during extraction (Weis-
senbacher et al., 2019), this step may also benefit
from simplification of the representation scheme.
Thus, we address two research questions:
RQ1 To what extent can fuzzy continuous repre-
sentation of discontinuous entities improve
NER of ADR? (intrinsic evaluation)
RQ2 To what extent can this fuzzy representation
benefit end-to-end ADR extraction? (extrinsic
evaluation)
In this paper we present FuzzyBIO, a fuzzy con-
tinuous BIO representation of discontinuous enti-
ties. Moreover, we show it is beneficial for end-to-
end ADR discovery. Our representation is applica-
ble to other domains as well. We release our code
for the purpose of follow-up research.2
2 Related Work
The first shared task to deal with discontinuous
medical entities was SemEval 2014 Task 7 (Prad-
han et al., 2014). Prior to this task, discontinuous
entities were often excluded (e.g. Uzuner et al.
(2011)) or each part was represented as a separate
continuous entity and later reassembled (Metke-
Jimenez and Karimi, 2015). Various representa-
tions were proposed but the only one able to dis-
tinguish between those that share a head word (i.e
composite entities) and those that do not (e.g. dis-
joint entities) was the BIOHD scheme (Zhang et al.,
2014).
2Code is available at: https://github.com/
AnneDirkson/FuzzyBIO
This scheme was later analysed in more detail
and compared to two baseline approaches: (1) ig-
noring all discontinuous entities and (2) represent-
ing separate parts of discontinuous entities as indi-
vidual entities (Tang et al., 2015). In comparison
to the baseline approaches, the BIOHD scheme
could improve recognition of both discontinuous
but also continuous entities, likely due to its ability
to distinguish between the two.
Tang et al. (2015) also proposed a further exten-
sion (BIOHD1234) in which numbers were added
to refer to which entity a non-head (‘D’) entity
should be combined with3, effectively expanding
the scheme from 7 to 13 tags. This representation
was able to outperform BIOHD due to its ability
to correctly represent multiple discontinuous enti-
ties and discontinuous entities with more than one
non-head part. However, as neither BIOHD nor
BIOHD1234 could handle multiple head entities in
one sentence, Tang et al. (2018) proposed a multi-
label BIO representation in which tokens can be
labeled with more than one tag, and each tag cor-
responds to one entity. For NER of adverse drug
responses, this novel representation managed to
outperform BIOHD. Similarly, Shang et al. (2020)
allowed for multiple labels per token for extracting
disorders from scientific articles.
Despite its limitations (Tang et al., 2018), the
BIOHD scheme is commonly adopted (Si et al.,
2019; Karimi et al., 2015; Zolnoori et al., 2019).
We propose an alternative, simpler representation
scheme that could improve extraction by being eas-
ier to learn.
3 Methods
3.1 The FuzzyBIO representation scheme
As displayed in Table 1, FuzzyBIO transforms dis-
continuous into continuous entities by annotating
31 and 2 denote nearest head and non-head entity on the
left, and 3 and 4 denote nearest head and non-head entity on
the right
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all tokens in between.4 Composite entities are com-
bined if they share an entity head. We realise this
compresses two separate entities into one (e.g. the
entities ‘pain in my hands’ and ‘pain in my upper
arms’ in Table 1). However, this does not pose a
problem to normalization, as the state-of-the-art
normalization method (Sung et al., 2020) includes
heuristic rules to split composite entities prior to
normalization.
3.2 Named Entity Recognition of ADR
For the NER task itself, we opt for distilBERT
(base-cased), a lighter more computationally effi-
cient version of BERT (Sanh et al., 2019). We use
a one-cycle learning rate (LR) policy (Smith, 2018)
with a maximum LR of 0.01. For each fold in the
10-fold cross-validation (CV), we select either 3 or
4 epochs based on the validation data. We use the
Huggingface implementation (Wolf et al., 2019)
with the wrapper ktrain (Maiya, 2020) to train our
models with the initialization seed set to 1.
3.3 Concept normalization of ADR
For normalization, we use the state-of-the-art
BioSyn method with default parameters (Sung
et al., 2020; Tutubalina et al., 2020). It is pos-
sible to provide composite entities as input, as this
method splits composite entities prior to normaliza-
tion using the heuristics by Souza and Ng (2015).
Our target ontology is SNOMED-CT5. As
SNOMED-CT is too extensive for our purpose, we
aim to map SNOMED concepts in our training data
to a curated subset of SNOMED, the CORE Prob-
lem List Subset6, before training the normalization
model. If there is a direct mapping in the commu-
nity based mappings in BioPortal (Noy et al., 2008)
between the original concept and a CORE concept
or the parent of the concept is in the CORE (e.g.
‘moderate anxiety’ to ‘anxiety’), we map the men-
tion to the respective CORE concept. We include
all concepts of the CORE subset and all concepts
that could not be mapped to a CORE concept in the
data as candidates. Synonyms for each concept are
retrieved from the community based mappings in
BioPortal (Noy et al., 2008) using the REST API
4In our data, we did not find any cases where an entity was
lost because it was in between two parts of another discon-
tinuous entity. Nonetheless, this is theoretically possible and





Entities CADEC PsyTAR CLEF
Continuous 5.360 4.508 16.261
Discontinuous
– Disjoint 100 225 909
– Composite 828 70 286
Table 2: Size of data sets.
and from the UMLS using pymedtermino (Lamy
et al., 2015).
3.4 Evaluation
For evaluating the NER models on a token level,
our metrics are lenient and ignore the prefixes (B-
I- H- D-). Additionally, we evaluate performance
on an entity level. Following Magge et al. (2020),
an entity is considered a true positive if any part of
the annotated ADR text is correctly identified (i.e.
overlaps with the predicted ADR text). We evaluate
the end-to-end performance by calculating how
many entities were both extracted during NER and
normalized to the correct SNOMED-CT concept.
4 Data
We use two data sets of social media posts anno-
tated for ADR: CADEC (Karimi et al., 2015) and
PsyTAR (Zolnoori et al., 2019). The former was
also used by Tang et al. (2018). Both contain posts
from medical fora on AskaPatient.com. Addition-
ally, we used a data set of clinical records annotated
for disorder mentions, namely the SemEval 2014
Task 7 data (Pradhan et al., 2014) that builds on
the CLEF eHealth 2013 corpus used by Tang et al.
(2015). See Table 2 for more details. Data sets
were split into 10 folds stratified on the presence of
ADRs. For PsyTAR, we chose sentences as units
as they were annotated separately. For the CLEF
data set, each document was split into sequences of
5 sentences for the NER task, because of memory
restrictions on the input length for BERT models.
5 Results
5.1 Intrinsic evaluation
As can be seen in Table 3, the FuzzyBIO scheme
improves recall for two of three data sets, namely
for CADEC (+0.29) and CLEF (+0.07), at a cost
to precision (-0.24 and -0.1). For these data sets,
using FuzzyBIO also leads to a higher percentage
of correctly identified entities for both continuous
(+1.1 and +0.6) and discontinuous entities (+3.5
80
Token level Entity level recall
Data Scheme Micro F1 P R Continuous Disjoint Composite
CADEC BIOHD 0.586 0.636 0.555 42.0% 55.4% 64.6%FuzzyBIO 0.596 0.612 0.584 43.1% 58.9% 65.2%
PsyTAR BIOHD 0.771 0.751 0.797 87.4% 83.8% 79.5%FuzzyBIO 0.762 0.747 0.780 84.9% 84.4% 87.5%
CLEF BIOHD 0.312 0.286 0.345 35.6% 52.8% 69.1%FuzzyBIO 0.309 0.276 0.352 36.2% 55.2% 76.6%
Table 3: Intrinsic evaluation of NER. Results are the average of a 10 fold CV.
and +3.6 for disjoint and +0.6 and +0.7 for compos-
ite entities). For the remaining data set (PsyTAR),
overall NER performance is negatively affected by
using FuzzyBIO (-0.09) and continuous entities are
missed more often (-2.5). Nonetheless, also for
this data set discontinuous entities are extracted
correctly more often (+0.8 and +8.0) when using
FuzzyBIO instead of the BIOHD scheme.
5.2 Extrinsic evaluation
As can be seen in Table 4, using the FuzzyBIO
scheme improves end-to-end performance for con-
tinuous and composite entities in two of three data
sets, namely the CADEC (+0.4 and +1.3) and
CLEF data (+0.4 and +5.7). In contrast, the end-to-
end performance for disjoint entities is decreased
(-15.5 and -21.0) for these data sets despite initial
gains during NER. In the remaining data set (Psy-
TAR), the percentage of correctly identified enti-
ties after normalization is lower for all entity types
when using the FuzzyBIO instead of the BIOHD
scheme.
Entity level recall
Data Scheme Continuous Disjoint Composite
CADEC BIOHD 23.9% 35.9% 21.2%FuzzyBIO 24.3% 20.4% 22.5%
PsyTAR BIOHD 43.6% 26.1% 10.6%FuzzyBIO 42.8% 25.0% 7.5%
CLEF BIOHD 21.7% 25.8% 26.5%FuzzyBIO 22.1% 4.8% 32.2%
Table 4: Extrinsic evaluation of ADR extraction. Re-
sults are the average of a 10 fold CV.
6 Discussion
In answer to RQ1, we find that the FuzzyBIO
scheme benefits overall recall during NER for two
of the three data sets. For these data sets, it also
leads to a higher percentage of correctly identified
entities, both continuous and discontinuous. For
the third data set (PsyTAR), more discontinuous en-
tities are extracted correctly when using FuzzyBIO
compared to the BIOHD scheme. However, more
continuous entities are missed. In answer to RQ2,
we find that for the same two data sets (CADEC and
CLEF) the end-to-end ADR extraction is improved
for continuous and composite entities. However,
for the remaining data set (PsyTAR) the end-to-end
performance is lower for all entity types.
We believe that the difference between PsyTAR
and the other data sets may be related to either the
low number of discontinuous entities or the low
number of composite entities in the PsyTAR data,
which may have hindered the training of an NER
model for these entity types. An alternative expla-
nation is that FuzzyBIO is less beneficial for eas-
ier NER tasks: The initial NER performance with
BIOHD is far higher for PsyTAR (F1 of 0.771) than
for the other data sets (F1 of 0.586 and 0.312). The
difference between PsyTAR and the other data sets
is unlikely to be related to the relative percentage
of discontinuous entities, as this is similar to that
of the CLEF data (5.8 vs 6.2%), or the nature of
the data, as CADEC contains forum posts from the
same website.
Another result that stands out is the lower end-
to-end performance for disjoint entities when using
the FuzzyBIO scheme despite initial gains in the
extraction of disjoint entities for all data sets. We
suspect that normalization of these entities is made
more challenging by the words in between the dis-
joint parts of the entity that are now included in
the extracted entity. Therefore, in future work, we
plan to investigate post-processing steps such as
the removal of stop words which may improve the
normalization of the more noisy disjoint entities
represented with FuzzyBIO. As our representation
is applicable for representing any type of discontin-
uous entity, future work may also include testing
FuzzyBIO in other domains.
Although the improvement in NER is compa-
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rable for disjoint entities in medical records and
user-generated content, the negative impact on nor-
malization of disjoint entities is far stronger for the
medical records. One might expect the normaliza-
tion to decrease more strongly if more non-entity
words (i.e. more noise) were included, but the
median amount of non-entity words included in
the disjoint entities is equal for all data sets (on
average 1 word is added). Manual analysis also
does not reveal a difference between the type of
non-entity word included; They appear to mostly
be stopwords. Thus, the most likely explanation
for this difference is that the training examples for
normalization from the user-generated data are al-
ready more noisy than their counterparts from the
medical records. Consequently, the normalization
algorithm for user-generated data might be better at
dealing with noise. Future work could investigate
whether training with the noisy examples instead
of the original entities would be beneficial.
FuzzyBIO appears to be more beneficial for end-
to-end extraction of composite entities in the medi-
cal records (+5.7) than in the user-generated data
(+1.3 and -3.1). However, the number of non-entity
words that is included is not lower for the medical
records (median of 2 words added) compared to
the user-generated data (median of 1 for CADEC
and 3 for PsyTAR). Thus, this difference does not
appear to be due to an increase in the fuzziness of
the entities.
We also find some support for our hypothesis
that the BIOHD representation makes the NER task
more difficult for BERT models to learn than the
FuzzyBIO representation. Overall the BERT mod-
els have difficulty learning the additional tag types;
The precision for H- and D-tags is consistently
lower than the precision for B-tags. In fact, on
the PsyTAR data which contains only few overlap-
ping entities (1.7%), the H-tag was never predicted.
It seems that FuzzyBIO makes the task easier in
two ways, namely by standardizing entities into
continuous sequences that always start with a B-
tag and by excluding rare tags such as the H-tag.
Standardizing entities makes it easier for the model
to learn the underlying rules and excluding rare
tags removes a goal for which there are only few
examples available.
7 Conclusion
As recommendation for future NER tasks, we ex-
pect FuzzyBIO to especially benefit NER for diffi-
cult tasks with a fair amount of discontinuous enti-
ties. However, since the conversion from BIOHD
to FuzzyBIO is straightforward and deterministic,
we recommend to experimentally compare which
of the two representations is more effective for any
data set that includes discontinuous entities.
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